A study of the probit model with latent variables in Phase I clinical trials
From MaRDI portal
Recommendations
- A multivariate probit latent variable model for analyzing dichotomous responses
- A latent class probit model for analyzing pick any/N data
- Proportional Hazards Models: A Latent Competing Risk Approach
- Analysis of multivariate probit models
- A Biomedical Application of Latent Class Models with Random Effects
- A latent trait model for response times on tests employing the proportional hazards model
Cites work
- A phase I dose-finding study based on polychotomous toxicity responses
- Bayesian Analysis of Binary and Polychotomous Response Data
- Bayesian analysis of dichotomous quantal response models
- Consistency of continual reassessment method under model misspecification
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
- On the multivariate predictive distribution of multi-dimensional effective dose: a Bayesian approach
- Operating characteristics of the standard phase I clinical trial design.
- Sampling-Based Approaches to Calculating Marginal Densities
- Two-dimensional toxic dose and multivariate logistic regression, with application to decompression sickness
This page was built for publication: A study of the probit model with latent variables in Phase I clinical trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5220814)
